Cynthia Lynch, MD
Hematology & Oncology · Goodyear, AZNPI 1790726255
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,870 of the $6,602 with a category attached, or 73.8%. 9 manufacturers reported payments, led by Novartis at 57.0% of the total. Reporting peaked in 2020 at $3,344 and has fallen 96.7% since, to $112 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 19 payments — averaging $347.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- Pfizer$1K
- Daiichi Sankyo Inc.$1K
- Gilead$139
- R-pharm US LLC$56
- GSK$24
- plus $52 from 3 others
Across 315 payments — averaging $12,042 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.2M
- Merck$854K
- Seagen Inc.$735K
- Boehringer Ingelheim$638K
- Daiichi Sankyo Inc.$191K
- Macrogenics, Inc.$89K
- plus $110K from 6 others
What the payments were for
- Consulting fees$4,87074%
- Speaking & faculty fees$1,45022%
- Food & beverage$2704%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 2 | $3,760 |
| Pfizer | 3 | $1,461 |
| Daiichi Sankyo Inc. | 1 | $1,110 |
| Gilead | 8 | $139 |
| R-pharm US LLC | 1 | $56 |
| GSK | 1 | $24 |
| Seagen Inc. | 1 | $19 |
| AbbVie | 1 | $19 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,602 in reported general payments places this provider in the 45th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrserduElacestrant Hcl | 19 | $433,794 |
| IbrancePalbociclib | 23 | $355,298 |
| Letrozole | 168 | $4,560 |
| Tamoxifen Citrate | 60 | $1,732 |
| Exemestane | 15 | $1,482 |
| Anastrozole | 50 | $855 |
| Dexamethasone | 16 | $484 |
| Prochlorperazine Maleate | 20 | $206 |
| Ondansetron Hcl | 24 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $1,461 | $355,29823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Goodyear
- Govardhanan NagaiahGoodyear$222K
- Jeremy LarsenGoodyear$117K
- Sujith KalmadiChandler$1.4M
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
- Christopher ChenTucson$370K
- Rachna ShroffTucson$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.